| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 93 | 2024 | 871 | 12.070 |
Why?
|
| Kidney Failure, Chronic | 18 | 2022 | 430 | 2.560 |
Why?
|
| Pregnancy Complications | 11 | 2021 | 350 | 2.480 |
Why?
|
| Nephrology | 9 | 2024 | 46 | 2.390 |
Why?
|
| Immunosuppressive Agents | 29 | 2019 | 987 | 2.220 |
Why?
|
| Pregnancy Outcome | 10 | 2021 | 267 | 2.020 |
Why?
|
| Graft Rejection | 32 | 2021 | 1123 | 1.930 |
Why?
|
| Kidney Diseases | 13 | 2024 | 309 | 1.910 |
Why?
|
| Polyomavirus Infections | 10 | 2024 | 28 | 1.860 |
Why?
|
| BK Virus | 8 | 2024 | 23 | 1.580 |
Why?
|
| Living Donors | 15 | 2019 | 347 | 1.530 |
Why?
|
| Tumor Virus Infections | 8 | 2024 | 83 | 1.360 |
Why?
|
| Pre-Eclampsia | 4 | 2023 | 261 | 1.180 |
Why?
|
| Isoxazoles | 5 | 2011 | 78 | 1.070 |
Why?
|
| Kidney | 16 | 2023 | 1093 | 1.030 |
Why?
|
| Antiviral Agents | 6 | 2024 | 364 | 0.880 |
Why?
|
| Renal Dialysis | 9 | 2023 | 349 | 0.880 |
Why?
|
| Nephrology Nursing | 1 | 2024 | 1 | 0.850 |
Why?
|
| Humans | 135 | 2024 | 93138 | 0.830 |
Why?
|
| Pregnancy | 15 | 2023 | 3128 | 0.810 |
Why?
|
| Organ Transplantation | 5 | 2024 | 295 | 0.750 |
Why?
|
| Graft Survival | 12 | 2021 | 939 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2018 | 256 | 0.710 |
Why?
|
| Contraception | 2 | 2021 | 100 | 0.700 |
Why?
|
| Tissue Donors | 5 | 2021 | 541 | 0.670 |
Why?
|
| Critical Pathways | 1 | 2021 | 36 | 0.650 |
Why?
|
| Capparis | 1 | 2020 | 1 | 0.640 |
Why?
|
| Cardiovascular System | 1 | 2020 | 52 | 0.610 |
Why?
|
| Pancreas Transplantation | 8 | 2004 | 104 | 0.580 |
Why?
|
| Tacrolimus | 12 | 2019 | 372 | 0.580 |
Why?
|
| Female | 66 | 2024 | 48544 | 0.560 |
Why?
|
| Hypertension | 5 | 2017 | 748 | 0.550 |
Why?
|
| Risk Factors | 17 | 2023 | 5901 | 0.540 |
Why?
|
| Fertility | 3 | 2013 | 119 | 0.520 |
Why?
|
| Viremia | 1 | 2017 | 51 | 0.510 |
Why?
|
| Computers, Handheld | 2 | 2016 | 33 | 0.490 |
Why?
|
| Career Mobility | 1 | 2017 | 37 | 0.490 |
Why?
|
| Postoperative Complications | 11 | 2021 | 2552 | 0.490 |
Why?
|
| Midodrine | 1 | 2016 | 5 | 0.480 |
Why?
|
| Sexism | 1 | 2017 | 55 | 0.480 |
Why?
|
| Anemia | 3 | 2015 | 129 | 0.480 |
Why?
|
| DNA, Viral | 1 | 2017 | 234 | 0.480 |
Why?
|
| Kidney Function Tests | 2 | 2018 | 116 | 0.470 |
Why?
|
| Mentors | 1 | 2017 | 95 | 0.470 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 67 | 0.460 |
Why?
|
| Attitude to Health | 6 | 2018 | 214 | 0.450 |
Why?
|
| Allografts | 5 | 2023 | 205 | 0.450 |
Why?
|
| Parvoviridae Infections | 1 | 2015 | 5 | 0.450 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2015 | 13 | 0.440 |
Why?
|
| Leadership | 1 | 2017 | 149 | 0.440 |
Why?
|
| Nephritis, Interstitial | 5 | 2005 | 44 | 0.430 |
Why?
|
| Choice Behavior | 1 | 2016 | 159 | 0.430 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 122 | 0.430 |
Why?
|
| Mobile Applications | 1 | 2016 | 78 | 0.430 |
Why?
|
| Transplant Recipients | 3 | 2021 | 159 | 0.430 |
Why?
|
| Renal Insufficiency | 3 | 2016 | 97 | 0.430 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 185 | 0.410 |
Why?
|
| Donor Selection | 2 | 2018 | 81 | 0.410 |
Why?
|
| Middle Aged | 52 | 2024 | 27540 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 619 | 0.380 |
Why?
|
| Tissue and Organ Procurement | 6 | 2023 | 389 | 0.380 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 168 | 0.380 |
Why?
|
| United States | 15 | 2024 | 7581 | 0.370 |
Why?
|
| Patient Selection | 2 | 2016 | 688 | 0.370 |
Why?
|
| Male | 61 | 2024 | 44357 | 0.360 |
Why?
|
| Creatinine | 11 | 2017 | 293 | 0.360 |
Why?
|
| Fractures, Bone | 3 | 2008 | 154 | 0.360 |
Why?
|
| Cyclosporine | 7 | 2004 | 240 | 0.350 |
Why?
|
| Infant, Newborn | 4 | 2023 | 2427 | 0.340 |
Why?
|
| Adult | 49 | 2024 | 27850 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2015 | 557 | 0.340 |
Why?
|
| Pregnancy, High-Risk | 1 | 2011 | 16 | 0.330 |
Why?
|
| Nephrectomy | 7 | 2022 | 278 | 0.330 |
Why?
|
| Long-Term Care | 1 | 2011 | 63 | 0.330 |
Why?
|
| Time Factors | 15 | 2019 | 5379 | 0.320 |
Why?
|
| Survivors | 1 | 2011 | 204 | 0.310 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2012 | 38 | 0.300 |
Why?
|
| Polyomavirus | 2 | 2006 | 16 | 0.300 |
Why?
|
| Nephritis | 3 | 2018 | 17 | 0.300 |
Why?
|
| Bone Diseases | 3 | 2008 | 50 | 0.280 |
Why?
|
| Endpoint Determination | 2 | 2018 | 59 | 0.280 |
Why?
|
| Surveys and Questionnaires | 12 | 2019 | 2787 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2019 | 279 | 0.280 |
Why?
|
| Transplantation, Homologous | 14 | 2023 | 1014 | 0.270 |
Why?
|
| Antilymphocyte Serum | 4 | 2006 | 67 | 0.270 |
Why?
|
| Kidney Calculi | 2 | 2009 | 343 | 0.270 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 210 | 0.270 |
Why?
|
| Reproduction | 2 | 2006 | 205 | 0.270 |
Why?
|
| Treatment Outcome | 17 | 2024 | 9074 | 0.270 |
Why?
|
| Health Status | 4 | 2019 | 373 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1055 | 0.260 |
Why?
|
| Premature Birth | 3 | 2018 | 128 | 0.260 |
Why?
|
| Influenza, Human | 1 | 2010 | 347 | 0.250 |
Why?
|
| Immunocompromised Host | 2 | 2007 | 136 | 0.250 |
Why?
|
| Vitamin D Deficiency | 1 | 2008 | 107 | 0.250 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2021 | 247 | 0.240 |
Why?
|
| Smoking | 1 | 2010 | 647 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 916 | 0.230 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 648 | 0.230 |
Why?
|
| Biopsy | 11 | 2018 | 1172 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 550 | 0.220 |
Why?
|
| Public Opinion | 3 | 2015 | 50 | 0.220 |
Why?
|
| Hemodynamics | 6 | 1990 | 712 | 0.220 |
Why?
|
| Calcium Channel Agonists | 1 | 2004 | 13 | 0.220 |
Why?
|
| Research Design | 2 | 2018 | 620 | 0.220 |
Why?
|
| Societies, Nursing | 1 | 2024 | 2 | 0.210 |
Why?
|
| Azathioprine | 3 | 2004 | 122 | 0.210 |
Why?
|
| Breast Feeding | 3 | 2011 | 99 | 0.200 |
Why?
|
| Aged | 28 | 2024 | 20399 | 0.200 |
Why?
|
| Calcifediol | 1 | 2004 | 22 | 0.200 |
Why?
|
| Calcitriol | 1 | 2004 | 173 | 0.200 |
Why?
|
| Quality of Life | 5 | 2019 | 1776 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 1098 | 0.200 |
Why?
|
| Acute Disease | 5 | 2013 | 838 | 0.190 |
Why?
|
| Health Promotion | 1 | 2024 | 170 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 3 | 2024 | 282 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 301 | 0.180 |
Why?
|
| Complement C4b | 3 | 2013 | 33 | 0.180 |
Why?
|
| Family | 3 | 2014 | 319 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 1385 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 256 | 0.180 |
Why?
|
| Internet | 2 | 2015 | 345 | 0.180 |
Why?
|
| Consensus | 3 | 2019 | 366 | 0.170 |
Why?
|
| Coronary Disease | 7 | 1988 | 221 | 0.170 |
Why?
|
| Diabetes Mellitus | 3 | 2004 | 762 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 480 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 94 | 0.160 |
Why?
|
| Total Quality Management | 1 | 2000 | 31 | 0.160 |
Why?
|
| Organophosphonates | 3 | 2024 | 46 | 0.160 |
Why?
|
| B-Lymphocytes | 3 | 2021 | 703 | 0.160 |
Why?
|
| Hospitals, University | 3 | 2012 | 188 | 0.160 |
Why?
|
| Life Style | 2 | 2019 | 183 | 0.160 |
Why?
|
| Waiting Lists | 4 | 2018 | 211 | 0.160 |
Why?
|
| Delphi Technique | 2 | 2017 | 135 | 0.160 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2003 | 23 | 0.160 |
Why?
|
| Peptide Fragments | 3 | 2013 | 468 | 0.150 |
Why?
|
| Calcium | 1 | 2004 | 1173 | 0.150 |
Why?
|
| Drug Therapy, Combination | 6 | 2006 | 753 | 0.150 |
Why?
|
| Biological Variation, Individual | 1 | 2019 | 7 | 0.150 |
Why?
|
| Work Capacity Evaluation | 1 | 2019 | 5 | 0.150 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1999 | 18 | 0.150 |
Why?
|
| Cytosine | 3 | 2024 | 121 | 0.150 |
Why?
|
| Sick Leave | 1 | 2019 | 15 | 0.150 |
Why?
|
| Nephrolithiasis | 1 | 2019 | 24 | 0.150 |
Why?
|
| Infection Control | 1 | 2021 | 130 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 888 | 0.150 |
Why?
|
| Mental Health | 3 | 2019 | 187 | 0.150 |
Why?
|
| Blood Pressure | 5 | 2016 | 887 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2024 | 10132 | 0.150 |
Why?
|
| Sex Factors | 3 | 2018 | 1102 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.150 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 60 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2019 | 119 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 290 | 0.140 |
Why?
|
| Biological Products | 1 | 2021 | 178 | 0.140 |
Why?
|
| Bowman Capsule | 1 | 2018 | 6 | 0.140 |
Why?
|
| Heart Failure | 3 | 2019 | 1377 | 0.140 |
Why?
|
| Proteinuria | 1 | 2018 | 69 | 0.140 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1998 | 5 | 0.140 |
Why?
|
| Education | 1 | 2018 | 58 | 0.130 |
Why?
|
| Hospitals, Community | 1 | 1998 | 33 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2021 | 806 | 0.130 |
Why?
|
| Health Care Surveys | 2 | 2010 | 278 | 0.130 |
Why?
|
| Telemedicine | 1 | 2021 | 223 | 0.130 |
Why?
|
| Counseling | 2 | 2011 | 164 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 48 | 0.130 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2017 | 48 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 339 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 183 | 0.130 |
Why?
|
| Plasma Cells | 2 | 2012 | 84 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2021 | 590 | 0.130 |
Why?
|
| Steroids | 1 | 1998 | 166 | 0.130 |
Why?
|
| Fatigue | 1 | 2018 | 181 | 0.130 |
Why?
|
| Cadaver | 5 | 2007 | 195 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2017 | 34 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2018 | 181 | 0.120 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2018 | 83 | 0.120 |
Why?
|
| Income | 1 | 2017 | 86 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1786 | 0.120 |
Why?
|
| Personal Autonomy | 2 | 2014 | 120 | 0.120 |
Why?
|
| Minority Groups | 1 | 2017 | 149 | 0.120 |
Why?
|
| Crotonates | 2 | 2006 | 12 | 0.120 |
Why?
|
| Motivation | 2 | 2015 | 310 | 0.120 |
Why?
|
| Toluidines | 2 | 2006 | 18 | 0.120 |
Why?
|
| Hydroxybutyrates | 2 | 2006 | 25 | 0.110 |
Why?
|
| Caregivers | 1 | 2017 | 171 | 0.110 |
Why?
|
| Self Report | 2 | 2019 | 328 | 0.110 |
Why?
|
| Parvovirus B19, Human | 1 | 2015 | 3 | 0.110 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 18 | 0.110 |
Why?
|
| Inflammation | 1 | 2021 | 1049 | 0.110 |
Why?
|
| Aniline Compounds | 2 | 2006 | 59 | 0.110 |
Why?
|
| Health Personnel | 1 | 2017 | 234 | 0.110 |
Why?
|
| Nitriles | 2 | 2006 | 154 | 0.110 |
Why?
|
| Capillaries | 3 | 2005 | 83 | 0.110 |
Why?
|
| Parathyroid Hormone | 2 | 2008 | 227 | 0.110 |
Why?
|
| Adolescent | 9 | 2017 | 9550 | 0.110 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 56 | 0.110 |
Why?
|
| Pleura | 1 | 1995 | 30 | 0.110 |
Why?
|
| Compensation and Redress | 1 | 2015 | 27 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 1 | 2015 | 53 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 1995 | 42 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2019 | 1193 | 0.110 |
Why?
|
| Bupivacaine | 1 | 1995 | 48 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1994 | 201 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 170 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 1276 | 0.100 |
Why?
|
| Self Care | 1 | 2015 | 167 | 0.100 |
Why?
|
| Analgesia | 1 | 1995 | 64 | 0.100 |
Why?
|
| Focus Groups | 1 | 2015 | 184 | 0.100 |
Why?
|
| Obesity | 1 | 2021 | 1014 | 0.100 |
Why?
|
| Vitamin D | 2 | 2008 | 272 | 0.100 |
Why?
|
| Telenursing | 1 | 2013 | 2 | 0.100 |
Why?
|
| Culture | 1 | 2014 | 54 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2015 | 132 | 0.100 |
Why?
|
| Heart | 3 | 1990 | 522 | 0.100 |
Why?
|
| Plasma Exchange | 1 | 2013 | 28 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 433 | 0.100 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2013 | 35 | 0.100 |
Why?
|
| Cell Phone | 1 | 2013 | 39 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1769 | 0.100 |
Why?
|
| Aminoglycosides | 1 | 2013 | 31 | 0.100 |
Why?
|
| Sexuality | 1 | 2013 | 40 | 0.100 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2013 | 37 | 0.100 |
Why?
|
| Piperidines | 2 | 1985 | 163 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 750 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2019 | 814 | 0.100 |
Why?
|
| Awareness | 1 | 2013 | 89 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 52 | 0.100 |
Why?
|
| Immunologic Memory | 1 | 2014 | 184 | 0.090 |
Why?
|
| Vancomycin | 1 | 2013 | 75 | 0.090 |
Why?
|
| Triglycerides | 2 | 1992 | 231 | 0.090 |
Why?
|
| Minerals | 1 | 2012 | 21 | 0.090 |
Why?
|
| Isoantibodies | 1 | 2013 | 127 | 0.090 |
Why?
|
| Cholesterol, HDL | 2 | 1992 | 173 | 0.090 |
Why?
|
| Bone Density | 2 | 2004 | 236 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2013 | 228 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 561 | 0.090 |
Why?
|
| Cesarean Section | 1 | 2013 | 158 | 0.090 |
Why?
|
| Nursing Staff, Hospital | 1 | 2012 | 44 | 0.090 |
Why?
|
| Reoperation | 5 | 2011 | 696 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2021 | 371 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1704 | 0.090 |
Why?
|
| Blood | 2 | 2006 | 68 | 0.090 |
Why?
|
| Cholesterol | 2 | 1992 | 364 | 0.090 |
Why?
|
| Fertilization | 1 | 2011 | 42 | 0.080 |
Why?
|
| Immunization Schedule | 1 | 2010 | 23 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2021 | 3044 | 0.080 |
Why?
|
| Ethics, Medical | 3 | 2008 | 291 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 381 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3815 | 0.080 |
Why?
|
| Nicardipine | 1 | 1990 | 6 | 0.080 |
Why?
|
| Young Adult | 7 | 2017 | 6922 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 889 | 0.080 |
Why?
|
| Prevalence | 2 | 2008 | 1318 | 0.080 |
Why?
|
| Infertility, Female | 1 | 2010 | 98 | 0.070 |
Why?
|
| Virus Replication | 2 | 2011 | 284 | 0.070 |
Why?
|
| Hematuria | 1 | 2009 | 49 | 0.070 |
Why?
|
| Heart Ventricles | 4 | 1990 | 649 | 0.070 |
Why?
|
| CD3 Complex | 3 | 2012 | 135 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 451 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 237 | 0.070 |
Why?
|
| Rabbits | 2 | 2006 | 579 | 0.070 |
Why?
|
| Muromonab-CD3 | 4 | 1997 | 70 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 3891 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2009 | 80 | 0.070 |
Why?
|
| Biomarkers | 2 | 2013 | 1905 | 0.070 |
Why?
|
| Mycophenolic Acid | 2 | 1998 | 85 | 0.070 |
Why?
|
| Siblings | 1 | 2008 | 108 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 833 | 0.070 |
Why?
|
| Age Factors | 3 | 2019 | 1896 | 0.070 |
Why?
|
| Acecainide | 1 | 1987 | 1 | 0.060 |
Why?
|
| Procainamide | 1 | 1987 | 4 | 0.060 |
Why?
|
| Preconception Care | 1 | 2007 | 8 | 0.060 |
Why?
|
| Delayed Graft Function | 1 | 2006 | 16 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2019 | 4546 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2007 | 90 | 0.060 |
Why?
|
| Animals | 9 | 2021 | 27965 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 1849 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2006 | 20 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2006 | 49 | 0.060 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2006 | 77 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 83 | 0.060 |
Why?
|
| Quinolones | 1 | 2006 | 57 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2006 | 80 | 0.060 |
Why?
|
| Urine | 1 | 2006 | 91 | 0.060 |
Why?
|
| Chicago | 3 | 2018 | 1452 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 981 | 0.060 |
Why?
|
| Immune System | 1 | 2006 | 101 | 0.050 |
Why?
|
| Incidence | 1 | 2009 | 1698 | 0.050 |
Why?
|
| Fetus | 1 | 2006 | 234 | 0.050 |
Why?
|
| Costs and Cost Analysis | 3 | 2021 | 154 | 0.050 |
Why?
|
| Radius | 1 | 2004 | 30 | 0.050 |
Why?
|
| Femur Neck | 1 | 2004 | 42 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2007 | 297 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 109 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1727 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1984 | 71 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2015 | 346 | 0.050 |
Why?
|
| Registries | 2 | 2018 | 995 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 46 | 0.050 |
Why?
|
| Recurrence | 5 | 2003 | 1188 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2003 | 149 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 940 | 0.050 |
Why?
|
| Thallium | 1 | 1982 | 5 | 0.050 |
Why?
|
| Dipyridamole | 1 | 1982 | 12 | 0.050 |
Why?
|
| Verapamil | 1 | 1982 | 32 | 0.050 |
Why?
|
| Propranolol | 1 | 1982 | 42 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 627 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 9 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 465 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 20 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 1908 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1982 | 106 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 31 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2024 | 472 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 355 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 187 | 0.040 |
Why?
|
| Decision Making | 2 | 2018 | 671 | 0.040 |
Why?
|
| Physicians | 1 | 2008 | 668 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 985 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2827 | 0.040 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2000 | 4 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 171 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 104 | 0.040 |
Why?
|
| Granuloma | 1 | 2000 | 64 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 496 | 0.040 |
Why?
|
| California | 1 | 2000 | 157 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 207 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2021 | 276 | 0.040 |
Why?
|
| Medical Records | 1 | 2000 | 121 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2019 | 5 | 0.040 |
Why?
|
| Data Collection | 2 | 2014 | 370 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1160 | 0.040 |
Why?
|
| Radionuclide Imaging | 4 | 1985 | 180 | 0.040 |
Why?
|
| Public Sector | 1 | 2019 | 13 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 45 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 303 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 117 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2015 | 2434 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 81 | 0.040 |
Why?
|
| Stroke Volume | 4 | 1987 | 434 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 200 | 0.040 |
Why?
|
| Social Participation | 1 | 2019 | 16 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 23 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1990 | 109 | 0.030 |
Why?
|
| Fear | 1 | 2018 | 87 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 43 | 0.030 |
Why?
|
| APACHE | 1 | 1998 | 23 | 0.030 |
Why?
|
| Brazil | 1 | 1998 | 81 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 241 | 0.030 |
Why?
|
| Drainage | 2 | 1998 | 170 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 120 | 0.030 |
Why?
|
| Research Report | 1 | 2018 | 43 | 0.030 |
Why?
|
| Duodenum | 1 | 1998 | 111 | 0.030 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1997 | 20 | 0.030 |
Why?
|
| Portal Vein | 1 | 1998 | 119 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 234 | 0.030 |
Why?
|
| Body Weight | 1 | 1998 | 449 | 0.030 |
Why?
|
| Survival Rate | 2 | 1998 | 1945 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 873 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 1519 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1998 | 175 | 0.030 |
Why?
|
| Heart Rate | 3 | 1985 | 507 | 0.030 |
Why?
|
| Actins | 1 | 1999 | 467 | 0.030 |
Why?
|
| Mice | 4 | 2021 | 12224 | 0.030 |
Why?
|
| Lipoprotein(a) | 2 | 1993 | 28 | 0.030 |
Why?
|
| Rats, Inbred Lew | 2 | 1994 | 214 | 0.030 |
Why?
|
| Cardiac Catheterization | 3 | 1987 | 295 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 192 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1995 | 16 | 0.030 |
Why?
|
| Skin Transplantation | 2 | 1994 | 191 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 99 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 1998 | 480 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 120 | 0.030 |
Why?
|
| Crime | 1 | 2015 | 38 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 7039 | 0.030 |
Why?
|
| Flecainide | 2 | 1985 | 7 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2015 | 69 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 404 | 0.030 |
Why?
|
| Victoria | 1 | 2014 | 5 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 190 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2015 | 120 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 140 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2014 | 72 | 0.030 |
Why?
|
| Software | 1 | 2018 | 669 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 192 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 236 | 0.030 |
Why?
|
| Exercise Test | 3 | 1988 | 151 | 0.030 |
Why?
|
| Videodisc Recording | 1 | 2013 | 2 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 178 | 0.030 |
Why?
|
| Morphine | 1 | 1995 | 127 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1206 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2013 | 15 | 0.030 |
Why?
|
| Catheterization | 1 | 1995 | 217 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2013 | 90 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 1529 | 0.020 |
Why?
|
| Text Messaging | 1 | 2013 | 34 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1003 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 1980 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 165 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 33 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 1993 | 89 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 573 | 0.020 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Iran | 1 | 2012 | 17 | 0.020 |
Why?
|
| Electrophysiology | 2 | 1990 | 389 | 0.020 |
Why?
|
| Blood Glucose | 2 | 1996 | 866 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 320 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 618 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2003 | 291 | 0.020 |
Why?
|
| Prednisone | 3 | 1997 | 242 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 368 | 0.020 |
Why?
|
| Electrocardiography | 3 | 1982 | 499 | 0.020 |
Why?
|
| Plasma Substitutes | 1 | 1991 | 8 | 0.020 |
Why?
|
| Workload | 1 | 2012 | 126 | 0.020 |
Why?
|
| Atropine | 1 | 1991 | 53 | 0.020 |
Why?
|
| Vagus Nerve | 1 | 1991 | 44 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 875 | 0.020 |
Why?
|
| Cardiac Tamponade | 1 | 1991 | 19 | 0.020 |
Why?
|
| Cytokines | 1 | 1995 | 862 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 106 | 0.020 |
Why?
|
| Aortic Rupture | 1 | 1991 | 52 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1991 | 90 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1991 | 136 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 1990 | 12 | 0.020 |
Why?
|
| Chemistry | 1 | 1990 | 46 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1990 | 65 | 0.020 |
Why?
|
| Kidney Glomerulus | 2 | 2003 | 121 | 0.020 |
Why?
|
| Rats | 2 | 1994 | 4028 | 0.020 |
Why?
|
| Amiodarone | 1 | 1989 | 14 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1995 | 2020 | 0.020 |
Why?
|
| Reference Values | 1 | 1990 | 603 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1988 | 18 | 0.020 |
Why?
|
| Myocardial Contraction | 2 | 1987 | 188 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 1994 | 3430 | 0.020 |
Why?
|
| Propanolamines | 1 | 1988 | 21 | 0.020 |
Why?
|
| Fluorobenzenes | 1 | 1988 | 34 | 0.020 |
Why?
|
| Bioethics | 1 | 2008 | 37 | 0.020 |
Why?
|
| Aortography | 1 | 1987 | 57 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1910 | 0.020 |
Why?
|
| Polycythemia | 1 | 2007 | 7 | 0.020 |
Why?
|
| Portugal | 1 | 2007 | 25 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1987 | 25 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1988 | 255 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1988 | 195 | 0.020 |
Why?
|
| Ventricular Function | 1 | 1987 | 41 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1990 | 375 | 0.020 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1987 | 128 | 0.010 |
Why?
|
| Echocardiography | 2 | 1987 | 748 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 46 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 1985 | 97 | 0.010 |
Why?
|
| Fibrosis | 1 | 2005 | 228 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1985 | 117 | 0.010 |
Why?
|
| Tachycardia | 1 | 1984 | 36 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1997 | 913 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1988 | 798 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1983 | 16 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2003 | 31 | 0.010 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2003 | 36 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 161 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2003 | 91 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1982 | 38 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 941 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1982 | 39 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 154 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 334 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2002 | 158 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 436 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 226 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 61 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 195 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 303 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 59 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2001 | 122 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2001 | 168 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2001 | 285 | 0.010 |
Why?
|
| Arterioles | 1 | 1999 | 25 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 725 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 367 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 232 | 0.010 |
Why?
|
| Biological Availability | 1 | 1998 | 85 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1997 | 9 | 0.010 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 22 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1997 | 44 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1997 | 37 | 0.010 |
Why?
|
| Fibrin | 1 | 1997 | 86 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1997 | 58 | 0.010 |
Why?
|
| Confidentiality | 1 | 1997 | 75 | 0.010 |
Why?
|
| Child | 1 | 2008 | 7273 | 0.010 |
Why?
|
| Cineangiography | 2 | 1987 | 11 | 0.010 |
Why?
|
| Neutrophils | 1 | 1997 | 324 | 0.010 |
Why?
|
| Antibodies | 1 | 1997 | 346 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 1260 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1997 | 360 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 1995 | 36 | 0.010 |
Why?
|
| Monitoring, Immunologic | 1 | 1995 | 19 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 827 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1997 | 353 | 0.010 |
Why?
|
| Informed Consent | 1 | 1997 | 276 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1994 | 24 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1994 | 73 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1994 | 39 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1995 | 163 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1996 | 1518 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1995 | 453 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1993 | 271 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 688 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1991 | 17 | 0.010 |
Why?
|
| Plasminogen | 1 | 1991 | 45 | 0.010 |
Why?
|
| Angiography | 1 | 1988 | 192 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1987 | 22 | 0.000 |
Why?
|
| History, 20th Century | 1 | 1989 | 312 | 0.000 |
Why?
|
| Fistula | 1 | 1983 | 42 | 0.000 |
Why?
|
| Rest | 1 | 1982 | 50 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1983 | 232 | 0.000 |
Why?
|